GT Biopharma, Inc. GTBP
At closeNov 3, 2026, 4:44 PM EST
After hours · Nov 3, 4:44 PM ET
- YTD
- +571.34%
- 1 year
- +745.91%
- Market cap
- 10.86M
- EPS (ttm)
- -150.64
- Shares out
- 2.23M
- Forward P/E
- -0.26
- YTD return
- +571.34%
- 1-year return
- +745.91%
- Volume
- 41.53K
- Avg volume
- 64.96K
- Open
- 5.16
- Previous close
- 5.13
- Day's range
- 5.05 – 5.32
- 52-week range
- 4.91 – 28.75
- Beta
- 0.57
- Price target
- 11.00 (+108.7%)
- Earnings date
- Apr 4, 2024
2Y +2.22 (+72.79%)
Key statistics
- Enterprise value
- -2.72M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.52
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -8.04M
- Total cash
- 9.25M
- Total debt
- 0
- Return on equity
- -131.48%
- Short % of float
- 0.81%
- 50-day average
- 2.76
- 200-day average
- 3.00
Analyst view
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Apr 4, 2024
Expected Apr 4, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -1.53 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -2.24 | — | — |
| May 15, 2024 | Mar 1, 2024 | -2.70 | -2.12 | +0.58 | +21.48% |
| Apr 4, 2024 | Dec 1, 2023 | -2.70 | — | — | — |
| Nov 1, 2023 | Sep 1, 2023 | -3.00 | -1.80 | +1.20 | +40.00% |
| Aug 7, 2023 | Jun 1, 2023 | -3.00 | -2.70 | +0.30 | +10.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 2, 2024 | Roth MKM | init | — | Buy |
About GT Biopharma, Inc.
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- gtbiopharma.com
News
GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
12 Health Care Stocks Moving In Tuesday's Intraday Session 
GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma 
EXCLUSIVE: GT Biopharma Announces Potential New Indication for GTB-5550, A B7-H3-Targeted Natural Killer Cell Engager, For Multiple Myeloma; FDA Clearance Under Investigator Sponsored Trial Protocol 
EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy 
12 Health Care Stocks Moving In Monday's Intraday Session 
GT Biopharma, Inc. (GTBP) Discusses TriKE Platform, Clinical Progress, and the Case for NK Cell Immunotherapy Transcript - 12 Health Care Stocks Moving In Friday's Intraday Session
GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026
Your note
Sign in to keep a note on GTBP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BREEN MICHAEL MARTIN | Chief Executive Officer | Stock Award(Grant) | Aug 10, 2023 | 856,218 |
| OHRI MANU | Chief Financial Officer | Stock Award(Grant) | Aug 10, 2023 | 350,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| DekaBank Deutsche Girozentrale | 51.69% | 1,154,867 | 3.25M | Sep 29, 2024 |
| Bank of Montreal /CAN/ | 1.34% | 29,872 | 83.94K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.67% | 15,041 | 42.27K | Sep 29, 2024 |
| Vanguard Group Inc | 0.47% | 10,504 | 29.52K | Sep 29, 2024 |
| Wells Fargo & Company | 0.45% | 10,013 | 28.14K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.45% | 10,105 | 28.39K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.50% | 11,201 | 31.47K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.47% | 10,504 | 29.52K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.10% | 2,196 | 6.17K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 1,152 | 3.24K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 255 | 716 | Oct 30, 2024 |
| Guggenheim Active Allocation Fund | 0.00% | 3 | 8 | Aug 30, 2024 |